Microbiome Agency Consulting firm Experts Specialists Consultancy

Innovate in the market for microbiome therapies

Alcimed’s teams have been exploring the microbiome and microbiota market for more than 10 years, and in particular the gut microbiota. From R&D to the marketing of their products, we support our customers in the realization of scientific state of the art, the orientation of R&D programs, the search for partners, the definition of commercial strategies or the launch of new products.

    Tell us about your uncharted territory

    You have a project and want to discuss it with our explorers, write us!

    One of our explorers will contact you shortly.

    They trust us


    The challenges related to the microbiome

    In recent years, the microbiome has been an important subject of work for many sectors and industries, including health. The gut microbiota in particular is an important scientific discovery in recent years and its development has been made possible by the development of high-throughput sequencing techniques and omics technologies allowing the analysis of the genome of microorganisms, coupled with much greater computing capacities than before. Interest in the gut microbiota is reflected in the number of scientific publications on the subject which have more than doubled over the past ten years.

    The essential role of the microbiome in the functioning of the body has been discovered. Bacteria of the gut microbiota not only transform food into energetic nutrients, but are also believed to control bone metabolism, epithelial repair, vessel maturation, synthesis of vitamins, enzymes and neurotransmitters. They would play a barrier role against pathogenic microorganisms and destroy toxic substances. Finally, the gut microbiota also participates in the development and maturation of the immune system and the central nervous system, and could have a role in the modulation of behavior.

    These discoveries open the way to new markets and in particular to innovative therapeutic solutions. The main challenges for the pharmaceutical industry, biotechs and the whole research community are:

    The human microbiome market is expected to reach $1.598 billion by 2028 and an annual growth rate of 21.3% between 2025 and 2028.

      Tell us about your uncharted territory

      You have a project and want to discuss it with our explorers, write us!

      One of our explorers will contact you shortly.

      How we support you in your projects related to the microbiome

      Alcimed helps its clients to seize the opportunities of this field, and in particular of the booming human microbiome market. We support various players in the healthcare sector, both human and animal, such as European, North American and Asian biopharmaceutical and pharmaceutical companies, but also CROs and start-ups. We also support manufacturers from other sectors such as the food and cosmetics industries in exploring the opportunities offered by the microbiome, all over the world.

      Our projects focus on many states of the art but also cover various themes such as product launches and commercial strategy, strategic positioning, market studies and the development of business plans, competitive analysis and the evaluation of opportunities and the search for partners.

      Examples of recent projects carried out for our clients in microbiome

      • Study of current and potential microbiome approaches for skin health for a pharmaceutical company

        The objective of our client, a stakeholder in the pharmaceutical industry, was to identify and analyze new opportunities among approaches and products related to the skin microbiome. Our team has provided a comprehensive picture of the microbiome market context and related approaches, developments and trends.

        Our investigation made it possible to identify the various strategic options for our client, as well as the associated products / services / communications / partnerships. These options were then prioritized in a collaborative workshop. The result for our client? An innovative positioning strategy in this skin microbiome market, and an associated action plan.

      • Identification and mapping of the main stakeholders active in the field of microbiota with applications in gastroenterology for a pharmaceutical company searching for partners

        One of our clients from the pharmaceutical industry wanted to identify and map the main stakeholders active in the field of microbiota, with an emphasis on the therapeutic area of gastroenterology. To do this, our team has adopted a three-step methodology.

        A first step consisted in mapping the various centers and structures of interest on the subject (centers of excellence, biotechs, SMEs, service providers, etc.) and already positioned or having experience in the field of microbiota with applications in gastroenterology. The second stage then aimed to assess the main strengths of the most relevant stakeholders for our client.

        Finally, the most interesting stakeholders for a partnership and a collaboration were selected, according to the needs and the objectives of our client. The latter was therefore able to identify the best partners to market its new product.

      • Development of the global strategy of an animal health industrial player in the management of infections, intestinal health and the microbiome

        Our team supported one of our clients active in the world of animal health in the development of its global strategy for the management of infections and intestinal health in relation to the microbiome.

        Alcimed carried out a literature search on the antibiotics market, its trends and alternatives in the context of bacterial infections. This initial research was supplemented by interviews with internal and external KOLs on the subject.

        As a result, we were able to assemble a comprehensive report on the current state of infection management called “Facts & Insights in Infection Management & Gut Health”, as well as identify and rank potential opportunities to explore. Finally, a detailed analysis of these opportunities and the promotion of collective intelligence through several workshops allowed us to formalize strategic recommendations for our client and its management.

      • Definition of the R&D strategy of a start-up focused on the microbiota

        The goal of the start-up we supported was to explore the possibilities of fecal microbiota transplantation (FMT) in the case of infectious diseases. Our client needed the first solid elements to guide its R&D, define the first promising therapeutic application projects, which were likely to convince an investor.

        To do this, our team carried out a state of the art of medical publications on the subject of the gut microbiota, identified the infectious diseases presenting a dysbiosis induced by antibiotics or infectious agents, and carried out several interviews with users and non-users of FMT in the field of infectious diseases. Finally, our team evaluated the potential opportunities of FMT in infectious diseases by building model business cases.

        With all of this analysis, we were able to help our client in defining its R&D strategy thanks to a better understanding of current practices and unmet needs in the field of FMT. It also benefited from substantiated arguments for its next fundraising campaigns.

      You have a project?

        Tell us about your uncharted territory

        You have a project and want to discuss it with our explorers, write us!

        One of our explorers will contact you shortly.

        To go further